Abstract
Scarce data are available on the association of mineralocorticoid receptor antagonist (MRA) use with outcomes in acute decompensated heart failure (ADHF). To investigate the association of MRA use with all-cause mortality and hospital readmission in patients with ADHF. This cohort study examines participants enrolled in the Kyoto Congestive Heart Failure (KCHF) registry, a physician-initiated, prospective, multicenter cohort study of consecutive patients admitted for ADHF, between October 1, 2014, and March 31, 2016, into 1 of 19 secondary and tertiary hospitals throughout Japan. To balance the baseline characteristics associated with the selection of MRA use, a propensity score-matched cohort design was used, yielding 2068 patients. Data analysis was conducted from April to August 2018. Prescription of MRA at discharge from the index hospitalization. Composite of all-cause death or heart failure hospitalization after discharge. Among 3717 patients hospitalized for ADHF, 1678 patients (45.1%) had received MRA at discharge and 2039 (54.9%) did not. After propensity score matching, 2068 patients (with a median [interquartile range] age of 80 [72-86] years, and of whom 937 [45.3%] were women) were included. In the matched cohort (n = 1034 in each group), the cumulative 1-year incidence of the primary outcome was statistically significantly lower in the MRA use group than in the no MRA use group (28.4% vs 33.9%; hazard ratio [HR], 0.81; 95% CI, 0.70-0.93; P = .003). Of the components of the primary outcome, the cumulative 1-year incidence of heart failure hospitalization was significantly lower in the MRA use group than in the no MRA use group (18.7% vs 24.8%; HR, 0.70; 95% CI, 0.60-0.86; P < .001), whereas no difference in mortality was found between the 2 groups (15.6% vs 15.8%; HR, 0.98; 95% CI, 0.82-1.18; P = .85). No difference in all-cause hospitalization was observed between the 2 groups (35.3% vs 38.2%; HR, 0.88; 95% CI, 0.77-1.01; P = .07). In additional analyses that stratified by left ventricular ejection fraction, the association of MRA use with the primary outcome was statistically significant in patients with left ventricular ejection fraction of 40% or greater. Use of MRA at discharge from ADHF hospitalization did not appear to be associated with lower mortality but was associated with a lower risk of heart failure readmission. This finding suggests that MRA treatment at discharge may have minimal, if any, clinical advantages.
Highlights
Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have been associated with reductions in mortality in patients with stable chronic heart failure with reduced ejection fraction (HFrEF).[1,2] In patients with stable heart failure with preserved ejection fraction (HFpEF), a randomized clinical trial (RCT) has suggested that mineralocorticoid receptor antagonist (MRA) is associated with reductions in heart failure hospitalization, the study did not meet the primary composite end point of death from cardiovascular causes, aborted cardiac arrest, or heart failure hospitalization.[3,4]In contrast, scarce data are available on the long-term outcomes of MRA use after discharge of patients hospitalized for acute decompensated heart failure (ADHF).[5]
Of the components of the primary outcome, the cumulative 1-year incidence of heart failure hospitalization was significantly lower in the MRA use group than in the no MRA use group (18.7% vs 24.8%; hazard ratio (HR), 0.70; 95% CI, 0.60-0.86; P < .001), whereas no difference in mortality was found between the 2 groups (15.6% vs 15.8%; HR, 0.98; 95% CI, 0.82-1.18; P = .85)
In additional analyses that stratified by left ventricular ejection fraction, the association of MRA use with the primary outcome was statistically significant in patients with left ventricular ejection fraction of 40% or greater
Summary
Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have been associated with reductions in mortality in patients with stable chronic heart failure with reduced ejection fraction (HFrEF).[1,2] In patients with stable heart failure with preserved ejection fraction (HFpEF), a randomized clinical trial (RCT) has suggested that MRA is associated with reductions in heart failure hospitalization, the study did not meet the primary composite end point of death from cardiovascular causes, aborted cardiac arrest, or heart failure hospitalization.[3,4]In contrast, scarce data are available on the long-term outcomes of MRA use after discharge of patients hospitalized for acute decompensated heart failure (ADHF).[5]. Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have been associated with reductions in mortality in patients with stable chronic heart failure with reduced ejection fraction (HFrEF).[1,2] In patients with stable heart failure with preserved ejection fraction (HFpEF), a randomized clinical trial (RCT) has suggested that MRA is associated with reductions in heart failure hospitalization, the study did not meet the primary composite end point of death from cardiovascular causes, aborted cardiac arrest, or heart failure hospitalization.[3,4]. We sought to explore the association between MRA administered at discharge from ADHF hospitalization and clinical outcomes using the registry of a large contemporary all-comer study (Kyoto Congestive Heart Failure [KCHF]) in Japan of patients with ADHF hospitalization
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
